Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Lanxess

- PMLiVE

Merck KGaA given FDA Fast Track designation for generalised myasthenia gravis drug

Cladribine capsules could become the first ever oral treatment for gMG

- PMLiVE

AXON NAMES NEW PRESIDENT AND MANAGING PARTNER, TINA HAHN, AS RALPH SUTTON CHANGES LANE

April 30, 2025—Tina Hahn, who joined AXON in 2012 as Vice President, will now take on the role of AXON’s President and Managing Partner.

AXON

- PMLiVE

Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

- PMLiVE

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

The neurological disorder affects more than 150,000 people in the UK

- PMLiVE

Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type

The companies entered into a licensing agreement for the candidate in December last year

- PMLiVE

Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

- PMLiVE

Merck KGaA and Caris enter oncology partnership worth over $1.4bn

The alliance is aimed at accelerating the development of ADCs for cancer patients

- PMLiVE

Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m

The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins

- PMLiVE

Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront

Ompenaclid is in phase 2 development to treat advanced or metastatic colorectal cancer

- PMLiVE

Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m

The candidate is currently in late-stage development for tenosynovial giant cell tumour

- PMLiVE

New study finds dose of subcutaneous cladribine could predict MS relapse risk

The disease affects approximately 130,000 people in the UK and currently has no cure

- PMLiVE

Merck KGaA and Hengrui Pharmaceuticals announce oncology partnership worth over €1.4bn

The deal includes a next-generation PARP1 inhibitor and an antibody drug conjugate

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links